

1801 6500

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11373

In Re Application Of: Tracy Willson et al.

Serial No.
09/051,843

Filing Date
April 22, 1998

Examiner
to be assigned

Group Art Unit
to be assigned

IN THE U.S. PATENT & TRADEMARK OFFICE
A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

SEP 08 1998

PATENT & TRADEMARK OFFICE
C25 E

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

SEP 28 1998

GROUP 1801

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(b)

2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

a certification as specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11373

In Re Application Of: Tracy Willson et al.

Serial No.
09/051,843

Filing Date
April 22, 1998

Examiner
to be assigned

Group Art Unit
to be assigned

1 P
Title: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME
SEP 08 1998
PATENT & TRADEMARK OFFICE
CPS 3253

Payment of Fee
(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

RECEIVED
SEP 28 1999
GROUP 1800

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on September 4, 1998 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

FDG

Signature of Person Mailing Correspondence

Frank S. DiGiglio

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Signature

Dated: September 4, 1998

Frank S. DiGiglio, Reg. No. 31,346
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

CC:

#6
11/12/98
Mh

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy Willson et al. **Docket:** 11373

Serial No.: 09/051,843 **Dated:** September 4, 1998

Filed: April 22, 1998

For: A NOVEL HAEMOPOIETIN
RECEPTOR AND GENETIC
SEQUENCES ENCODING SAME

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following disclosures, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. N.A. Nicola (1994) *Guidebook to Cytokines and Their Receptors* Oxford University Press: New York, New York.

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on September 4, 1998.

Dated: September 4, 1998


Frank S. DiGiglio

2. N. Vita et al. (1995) "Characterization and Comparison of the Interleukin 13 Receptor With the Interleukin 4 Receptor on Several Cell Types" *The Journal of Biological Chemistry* 270 (8): 3512-3517;
3. N. Harada et al. (1990) "Expression Cloning of a cDNA Encoding the Murine Interleukin 4 Receptor Based on Ligand Binding" *Proc. Nat'l. Acad. Sci. USA* 87: 857-861;
4. D. Caput et al. (1996) "Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain" *Journal of Biological Chemistry* 271 (28): 16921-16926; and
5. International Publication No. WO 96/11213, dated April 18, 1996, to Amgen Boulder, Inc.

Applicants are also enclosing a copy of a Search Report and an International Preliminary Examination Report issued relative to the counterpart application, International Application No. PCT/AU96/00668, along with copies of the aforementioned disclosures.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herewith may be material to the examination of the present application as defined under 35 U.S.C. § 1.56(a).

Inasmuch as this Information Disclosure Statement is being submitted prior to the issuance of an Official Action on the merits, no petition, certification or fee is required.

Respectfully submitted,


Frank S. DiGilio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

FSD/XZ:mgl